Drug Search Results
Using advanced filters...
Advanced Search [+]

Verinurad

Alternative Names: verinurad, rdea3170
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: URAT1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gout|Kidney Failure, Chronic|Heart Failure, Diastolic|Heart Failure, Chronic|Type 2 Diabetes|Albuminuria|Kidney Diseases

Phase 1: Kidney Failure, Chronic|Gout|Healthy Volunteers|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AMETHYST

P2

Completed

Heart Failure, Diastolic|Heart Failure, Chronic

2022-04-29

AMETHYST

P2

Completed

Heart Failure, Diastolic|Heart Failure, Chronic

2022-04-29

SAPPHIRE

P2

Completed

Kidney Failure, Chronic

2021-11-22

SAPPHIRE

P2

Completed

Kidney Diseases

2021-11-22

Recent News Events